latest
outbreak
ebola
viru
diseas
west
africa
monoclon
antibodi
therapi
eg
zmapp
util
treat
patient
howev
due
antigen
differ
among
five
ebolaviru
speci
current
therapeut
monoclon
antibodi
effect
virus
speci
zair
ebolaviru
although
particular
speci
inde
caus
major
human
infect
central
recent
west
africa
ebolaviru
speci
eg
sudan
ebolaviru
bundibugyo
ebolaviru
also
repeatedli
caus
outbreak
central
africa
thu
neglect
develop
countermeasur
ebolavirus
report
gener
ebolaviru
glycoproteinspecif
monoclon
antibodi
effect
inhibit
cellular
entri
repres
isol
known
ebolaviru
speci
vitro
show
protect
efficaci
mous
model
ebolaviru
infect
novel
neutral
monoclon
antibodi
target
highli
conserv
intern
fusion
loop
glycoprotein
molecul
prevent
membran
fusion
viral
envelop
cellular
membran
discoveri
highli
crossneutr
antibodi
provid
promis
option
broadact
ebolaviru
antibodi
therapi
acceler
design
improv
vaccin
select
elicit
crossneutr
antibodi
multipl
speci
ebolavirus
ebolavirus
member
famili
filovirida
caus
sever
hemorrhag
fever
human
nonhuman
primat
human
case
fatal
rate
proven
latest
epidem
ebola
viru
diseas
evd
west
africa
ebolavirus
pose
signific
public
health
concern
howev
effect
prophylaxi
treatment
evd
yet
commerci
avail
five
distinct
speci
known
genu
ebolaviru
zair
ebolaviru
sudan
ebolaviru
forest
ebolaviru
bundibugyo
ebolaviru
reston
ebolaviru
repres
ebola
viru
ebov
sudan
viru
sudv
forest
viru
tafv
bundibugyo
viru
bdbv
reston
viru
restv
respect
ebov
sudv
bdbv
caus
evd
outbreak
increas
frequenc
central
west
africa
last
decad
ebolavirus
express
singl
transmembran
glycoprotein
gp
respons
receptor
bind
membran
fusion
thu
known
target
neutral
antibodi
gp
undergo
proteolyt
cleavag
host
proteas
furin
result
two
subunit
link
disulfid
bond
subunit
amino
acid
contain
core
glycoprotein
receptor
bind
domain
rbd
glycan
cap
larg
mucinlik
domain
extend
around
rbd
amino
acid
subunit
contain
intern
fusion
loop
ifl
heptad
repeat
transmembran
region
tm
cytoplasm
tail
ct
transport
ebolaviru
particl
late
endosom
low
ph
lead
proteolyt
process
gp
host
cystein
proteas
cathepsin
expos
receptor
bind
site
proteolyt
digest
gp
thought
interact
host
receptor
niemann
pick
follow
membran
fusion
sever
studi
demonstr
administr
ebov
gpspecif
antibodi
protect
nonhuman
primat
lethal
ebov
infect
may
constitut
lead
treatment
option
evd
human
west
african
evd
outbreak
ebov
gpspecif
monoclon
antibodi
mab
cocktail
eg
zmapp
use
treat
sever
patient
howev
character
therapeut
mab
date
ebov
gpspecif
crossneutr
activ
ebolaviru
speci
eg
sudv
scientif
report
doi
bdbv
demonstr
due
antigen
differ
among
speci
sinc
sudv
bdbv
also
shown
potenti
caus
public
health
emerg
sever
outbreak
central
africa
difficult
determin
prioriti
develop
countermeasur
ebolavirus
report
broadli
crossreact
gpspecif
mab
mab
recogn
put
epitop
highli
conserv
ifl
neutral
infect
repres
isol
known
ebolaviru
speci
inhibit
membran
fusion
demonstr
protect
potenti
therapeut
antibodi
mous
model
ebov
sudv
infect
vitro
properti
mab
crossreact
mab
select
screen
mous
hybridoma
supernat
thoroughli
crossneutr
activ
gpspecif
mab
mab
found
gpspecif
effici
neutral
infect
vesicular
stomat
viru
vsv
pseudotyp
gp
known
ebolavirus
ebov
sudv
tafv
bdbv
restv
includ
variant
caus
latest
outbreak
west
africa
marburg
viru
marv
relat
filoviru
caus
human
diseas
similar
evd
fig
inhibitori
concentr
ic
vsv
bear
sudv
tafv
bdbv
restv
gp
gml
respect
confirm
effect
neutral
infect
repres
authent
isol
known
ebolaviru
speci
fig
furthermor
bind
experi
ebov
gp
neutral
assay
ebov
gppseudotyp
vsv
reveal
possess
higher
bind
neutral
abil
ebov
gpspecif
mab
fig
shown
promis
protect
efficaci
anim
model
lethal
ebov
infect
identif
put
epitop
determin
put
epitop
mab
util
replicationcompet
recombin
vsv
contain
ebov
sudv
restv
gp
gene
put
epitop
success
determin
identifi
amino
acid
substitut
observ
antigen
variant
escap
neutral
antibodi
escap
mutant
ebov
gp
found
mutant
singl
amino
acid
substitut
glytoarg
glytoglu
amino
acid
posit
within
ifl
sequenc
subunit
fig
one
six
sudv
gp
escap
mutant
glytoarg
substitut
posit
sudv
gp
escap
mutant
alatothr
substitut
posit
fig
two
six
restv
gp
escap
mutant
glytoglu
substitut
posit
correspond
posit
ebov
gp
total
amino
acid
chang
found
restv
gp
escap
mutant
fig
use
revers
genet
approach
verifi
leutotrp
substitut
posit
critic
escap
neutral
supplementari
fig
amino
acid
posit
locat
tip
ifl
structur
ebov
sudv
restv
gp
indic
loop
structur
includ
residu
import
form
amino
acid
residu
green
blue
yellow
sphere
repres
gli
ala
leu
respect
critic
escap
mab
neutral
map
trimer
structur
gp
blue
red
monom
shown
ribbon
model
recognit
site
fig
confirm
bind
chimer
ebov
gp
whose
ifl
region
replac
marv
howev
show
bind
activ
synthet
peptid
correspond
amino
acid
ifl
ebov
gp
shown
suggest
epitop
may
partli
includ
conform
structur
importantli
amino
acid
sequenc
ifl
region
highli
conserv
among
current
known
ebolavirus
fig
provid
novel
target
univers
antibodi
therapi
evd
caus
humanpathogen
ebolavirus
ebov
sudv
tafv
bdbv
sinc
ifl
crucial
gpmediat
membran
fusion
assum
directli
inhibit
fusion
step
entri
process
ebolavirus
cell
confirm
analyz
inhibitori
effect
viral
attach
intern
membran
fusion
use
lipophil
tracer
dii
label
viruslik
particl
vlp
number
vlp
attach
surfac
vero
cell
significantli
differ
untreat
control
iggtreat
vlp
indic
interfer
vlp
attach
fig
supplementari
fig
likewis
number
vlp
coloc
late
endosom
marker
similar
suggest
affect
subsequ
uptak
cell
fig
e
supplementari
fig
final
analyz
membran
fusion
effici
detect
dequench
dii
fluoresc
observ
remark
enlarg
enhanc
dii
signal
coloc
cell
incub
untreat
control
iggtreat
vlp
indic
membran
fusion
occur
effici
endosom
fig
left
middl
panel
contrast
size
intens
dii
signal
vlp
significantli
reduc
indic
prevent
gpmediat
membran
fusion
fig
right
panel
f
supplementari
fig
protect
efficaci
mab
mous
model
final
investig
potenti
protect
mice
ebolaviru
infect
fig
immunocompet
balbc
mice
infect
lethal
dose
mouseadapt
ebov
treat
h
later
g
treat
anim
surviv
without
clinic
symptom
wherea
untreat
mice
succumb
infect
within
day
fig
evalu
crossprotect
potenti
wildtyp
ebov
sudv
infect
fig
sinc
immunocompet
mice
develop
diseas
upon
infect
wildtyp
ebolaviru
isol
interferon
receptor
knockout
ifnar
mice
use
purpos
found
ebov
sudv
caus
sever
weight
loss
untreat
mice
wherea
ebov
uniformli
caus
lethal
infect
treatment
h
infect
delay
onset
diseas
caus
ebolavirus
significantli
reduc
weight
loss
immunocompromis
mous
strain
mice
surviv
ebov
infect
neutral
antibodybas
therapi
test
anim
model
clinic
trial
particular
attent
given
highli
lethal
viral
diseas
passiv
immun
convalesc
serum
also
test
ebovinfect
patient
recent
studi
demonstr
effect
mab
treatment
nonhuman
primat
model
evd
gpspecif
mab
cocktail
zmapp
zmab
use
clinic
case
evd
outbreak
caus
ebov
belong
zair
ebolaviru
howev
mab
cocktail
expect
crossprotect
antigen
distinct
ebolavirus
hand
highli
crossreact
mab
known
ebolavirus
gener
previous
none
neutral
activ
studi
gener
novel
mab
crossneutr
activ
known
ebolavirus
show
reduc
infect
known
ebolavirus
vitro
higher
neutral
bind
activ
ebov
gpspecif
mab
inde
ic
valu
equal
lower
previous
report
neutral
mab
suggest
protect
capac
therapuet
mab
analyz
amino
acid
substitut
observ
antigen
variant
escap
determin
put
epitop
ifl
gp
molecul
may
overlap
partial
crossreact
gpspecif
mab
report
recent
accordingli
directli
inhibit
membran
fusion
induc
ebov
vlp
endosomeslysosom
ifl
structur
highli
conserv
speci
ebolavirus
indic
region
target
vaccin
therapeut
develop
ebolavirus
sinc
put
epitop
differ
previous
report
gpspecif
mab
use
passiv
immun
studi
may
provid
promis
option
compon
antibodi
cocktail
combin
previous
test
mab
demonstr
passiv
immun
protect
balbc
ifnar
mice
lethal
infect
ebov
ie
mouseadapt
wildtyp
ebov
respect
howev
crossprotect
potenti
could
evalu
diseas
sever
use
ifnar
mice
sinc
mouseadapt
sudv
caus
lethal
infect
immunocompet
mice
current
avail
sudv
uniformli
caus
lethal
infect
even
immunocompromis
mous
strain
found
passiv
immun
significantli
reduc
weight
loss
sudvinfect
mice
although
extent
promin
ebovinfect
mice
less
signific
protect
effect
seen
sudvinfect
mice
might
due
higher
ic
valu
sudv
ebov
thu
result
support
vitro
characterist
demonstr
effect
treatment
vivo
multipl
speci
ebolavirus
previou
studi
demonstr
immunocompromis
mice
treat
sever
time
g
mab
sudvspecif
mab
protect
sudv
infect
wherea
mice
treat
g
studi
thu
assum
protect
effect
sudv
could
improv
increas
dose
broadli
crossneutr
antibodi
recogn
common
epitop
share
among
current
known
ebolavirus
convert
humanmous
chimer
mab
promis
therapeut
candid
hand
gener
escap
mutant
vitro
speak
monotherapi
mab
scientif
report
doi
may
favor
develop
antibodi
cocktail
includ
futur
panebolaviru
therapi
virus
inde
report
combin
mab
help
avoid
appear
escap
variant
mab
recogn
distinct
epitop
detail
mechan
underli
antibodymedi
protect
ebolaviru
infect
need
elucid
discoveri
highli
crossreact
neutral
antibodi
put
epitop
report
provid
promis
option
develop
univers
evd
therapi
acceler
design
implement
improv
therapeut
vaccin
select
elicit
crossneutr
antibodi
multipl
speci
ebolavirus
purif
vlp
immun
cell
transfect
equal
amount
express
plasmid
encod
gp
matrix
protein
nucleoprotein
np
ebov
sudv
use
transit
reagent
miru
accord
manufactur
instruct
fortyeight
hour
later
cultur
supernat
harvest
centrifug
rpm
min
remov
cell
debri
vlp
purifi
cultur
supernat
ultracentrifug
rpm
rotor
beckman
h
sucros
cushion
vlp
pellet
suspend
phosphatebuff
salin
pb
fraction
sucros
gradient
pb
rpm
rotor
beckman
h
vlp
fraction
dilut
pb
sediment
ultracentrifug
rpm
rotor
h
final
vlp
pellet
resuspend
pb
gener
mab
fifteenweekold
femal
balbc
mice
immun
intraperiton
g
ebov
vlp
week
first
immun
mice
intraperiton
immun
g
ebov
vlp
week
first
immun
mice
immun
g
sudv
vlp
two
week
last
immun
mice
boost
intraperiton
g
ebov
vlp
three
day
later
mice
euthan
spleen
cell
mous
myeloma
cell
fuse
maintain
accord
standard
procedur
mice
treat
daili
gkg
rapamycin
intraperiton
start
week
prior
primari
immun
euthanasia
hybridoma
screen
secret
ebov
gpspecif
mab
neutral
test
vsv
pseudotyp
ebov
gp
hybridoma
produc
mab
clone
twice
limit
dilut
cell
hybridoma
produc
neutral
mab
screen
crossreact
filoviru
gp
mab
found
broadli
crossneutr
mab
purifi
mous
ascit
use
protein
agaros
column
biorad
anim
studi
carri
strict
accord
guidelin
proper
conduct
anim
experi
scienc
council
japan
protocol
approv
hokkaido
univers
anim
care
use
committe
enzymelink
immunosorb
assay
elisa
gpbase
elisa
perform
describ
previous
solubl
form
ebov
gp
purifi
use
antigen
mab
serial
dilut
pb
contain
tween
skim
milk
bound
antibodi
visual
horseradish
peroxidaseconjug
goat
antimous
igg
h
l
jackson
immunoresearch
tetramethylbenzidin
sigma
reaction
stop
ad
n
phosphor
acid
optic
densiti
nm
od
measur
use
softmax
pro
softwar
molecular
devic
tenfold
serial
dilut
rvsvebov
gp
rvsvsudv
gp
rvsvrestv
gp
incub
gml
mab
h
room
temperatur
inocul
confluent
vero
cell
grown
tissu
cultur
plate
adsorpt
h
cell
overlaid
eagl
minim
essenti
medium
invitrogen
contain
bacto
agar
bd
bovin
serum
albumin
sigma
uml
penicillin
mgml
streptomycin
gml
incub
day
mutant
virus
grow
presenc
mab
purifi
singl
isol
plaqu
highest
dilut
viru
propag
vero
cell
viral
rna
extract
supernat
nucleotid
sequenc
gp
gene
parent
virus
escap
mutant
determin
deduc
amino
acid
sequenc
compar
among
virus
ifl
amino
acid
sequenc
ebov
sudv
bdbv
tafv
restv
obtain
genbank
access
number
respect
substitut
amino
acid
posit
map
trimer
structur
gp
construct
use
discoveri
studio
biovia
base
crystal
structur
ebov
gp
pdb
code
sudv
restv
gp
structur
gener
homolog
model
base
ebov
gp
structur
model
gp
trimer
model
best
score
probabl
densiti
function
pdf
total
energi
chosen
model
evalu
use
purif
fluorescentlabel
vlp
purif
vlp
equal
amount
express
plasmid
ebov
np
gp
transfect
cell
use
transit
miru
fortyeight
hour
posttransfect
cultur
supernat
harvest
centrifug
rpm
min
remov
cell
debri
vlp
precipit
sucros
cushion
centrifug
rpm
h
rotor
beckman
precipit
vlp
suspend
pb
fraction
sucros
gradient
pb
rpm
rotor
beckman
h
one
ml
fraction
vlp
gml
incub
l
stock
solut
tetramethylindocarbocyanin
perchlor
dii
invitrogen
dark
h
room
temperatur
gentl
agit
vero
cell
express
cultur
mm
glassbottom
cultur
dish
mattek
corpor
diilabel
vlp
treat
gml
control
igg
mous
bd
bioscienc
h
room
temperatur
cell
wash
ml
phenol
redfre
dmem
invitrogen
incub
either
mab
control
iggtreat
untreat
vlp
medium
ice
min
follow
wash
medium
remov
unbound
vlp
incub
l
phenol
redfre
dmem
contain
fc
bovin
serum
albumin
h
analyz
attach
intern
membran
fusion
respect
assay
fluoresc
signal
enhanc
diilabel
vlp
envelop
fuse
endosom
membran
count
number
diilabel
vlp
cell
fix
paraformaldehyd
min
room
temperatur
nuclei
stain
use
gml
dihydrochlorid
dapi
min
room
temperatur
thermo
fisher
scientif
imag
acquir
oil
object
len
zeiss
invert
microscop
zen
softwar
carl
zeiss
measur
number
diilabel
vlp
imag
optic
section
acquir
micron
step
number
dii
signal
determin
approxim
individu
cell
approxim
dotscel
averag
number
per
cell
calcul
condit
coloc
analysi
percentag
diilabel
vlp
coloc
vesicl
measur
use
coloc
modul
zen
softwar
carl
zeiss
number
size
fluoresc
intens
dii
dot
analyz
metamorph
softwar
molecular
devic
rel
size
intens
dii
dot
determin
defin
valu
untreat
cell
passiv
immun
protect
efficaci
mice
balbc
mice
femal
week
old
inocul
mouseadapt
ebov
ffu
intraperiton
ip
inject
total
volum
l
one
day
infect
mice
treat
g
mab
ip
volum
l
investig
potenti
protect
mice
ebov
sudv
infect
ifnar
mice
chosen
studi
known
suscept
ebov
sudv
infect
bdbv
caus
clinic
symptom
ifnar
mice
data
shown
ifnar
mice
male
femal
week
old
treat
g
mab
ip
volum
l
one
day
infect
ffu
sudv
ffu
anim
monitor
sign
ill
weigh
daili
surviv
mice
euthan
day
infect
serum
collect
serolog
research
approv
conduct
complianc
guidelin
niaidrml
institut
anim
care
use
committe
iacuc
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
aaalac
approv
offic
laboratori
anim
welfar
olaw
assur
procedur
conduct
train
personnel
supervis
veterinarian
invas
clinic
procedur
perform
anim
anesthet
earli
endpoint
criteria
specifi
iacuc
approv
score
paramet
use
determin
anim
human
euthan
statist
analysi
data
analyz
use
graphpad
prism
softwar
viral
attach
intern
membran
fusion
experi
student
ttest
use
evalu
differ
control
igg
assess
weight
loss
mice
perform
repeatedmeasur
analysi
varianc
anova
follow
multipl
ttest
compar
averag
weight
untreat
control
mice
time
point
use
holmsidak
method
p
valu
less
consid
statist
signific
